Any feedback?
Literature summary for 3.4.21.74 extracted from
- Analysis of fibrin formation and proteolysis during intravenous administration of ancrod (2000), Blood, 96, 2793-2802.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | ancrod currently under investigation for treatment of acute ischemic stroke, therapeutic doses results in the formation of soluble fibrin complexes that are degraded by plasmin | Calloselasma rhodostoma |
Natural Substrates/ Products (Substrates)
| Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| fibrinogen + H2O | Calloselasma rhodostoma | - |
fibrin + fibrinopeptide A | - |
? |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Calloselasma rhodostoma | - |
Malayan pit viper | - |
Purification (Commentary)
| Purification (Comment) | Organism |
|---|---|
- |
Calloselasma rhodostoma |
Source Tissue
| Source Tissue | Comment | Organism | Textmining |
|---|
Substrates and Products (Substrate)
| Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|
| fibrinogen + H2O | - |
Calloselasma rhodostoma | fibrin + fibrinopeptide A | - |
? | |
| additional information | does not cleave fibrinopeptide B and does not activate factor XIII | Calloselasma rhodostoma | ? | - |
? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
